Serum ficolin-2 in hospitalised patients with community-acquired pneumonia

James D. Chalmers (Lead / Corresponding author), Gilly B. Fleming, Julia Rutherford, Misao Matsushita, David C. Kilpatrick, Adam T. Hill

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)


    Mannose binding lectin (MBL) and ficolins contribute to host defence through activation of the lectin pathway of complement. In this study, serum levels of ficolin-2 and MBL were determined in 276 patients with community-acquired pneumonia (CAP). MBL deficiency and ficolin-2 insufficiency were defined using previously validated cut-offs. No differences were observed in MBL or ficolin-2 between patients and controls. MBL-deficient patients (≤500 ng/ml) were not at higher risk of 30-day mortality odds ratio (OR) 0.97 (0.38–2.48,p=0.9) or a composite outcome of mortality, mechanical ventilation, vasopressor support (MV/VS) or complications OR 0.89 (0.44–1.77, p=0.9). Although no significant relationship between ficolin-2 insufficiency and outcome was observed, very low ficolin-2 levels (≤1,200 ng/ml) were associated with an OR 1.23 (0.15–10.1), p=0.6 for 30-day mortality, 3.05 (0.61–15.2, p=0.2) for MV/VS and OR 2.05 (0.52–8.1, p=0.2) for the composite outcome. Low serum levels of MBL and ficolin-2 are not associated with CAP susceptibility. The high frequency of ficolin-2 insufficiency in patients with severe CAP would justify a larger investigation of ficolin-2 as a modifier of CAP severity.
    Original languageEnglish
    Pages (from-to)1635-1641
    Number of pages7
    Issue number5
    Early online date16 Apr 2014
    Publication statusPublished - Oct 2014


    Dive into the research topics of 'Serum ficolin-2 in hospitalised patients with community-acquired pneumonia'. Together they form a unique fingerprint.

    Cite this